Keefe Bruyette raised the firm’s price target on Marsh McLennan (MRSH) to $203 from $200 and keeps a Market Perform rating on the shares. The “Thrive” program should drive margin expansion in 2026 and 2027, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRSH:
- Marsh & McLennan Warns of Broad Risk Exposure That Could Materially Impact Financial Performance
- Marsh & McLennan Earnings Call Highlights Growth and AI
- Marsh & McLennan: Solid Near-Term Execution but Pricing Headwinds Limit Upside, Justifying Hold Rating
- Marsh McLennan reports Q1 adjusted EPS $3.29, consensus $3.22
- Marsh McLennan price target lowered to $174 from $181 at BofA